Depression Working Group 2.0 Presented at the 14th Annual PRO Consortium Workshop – Silver Spring, MD – April 19-20, 2023

Background

Rationale for Depression Working Group 2.0

- Due to the emergence of antidepressant agents with faster onsets of action, there is growing recognition of the need for well-defined and reliable assessment tools that can measure clinical benefit within shorter time frames, potentially within hours or days rather than weeks in treatment trials for major depressive disorder (MDD).
- With FDA qualification of the 7-day recall period Symptoms of Major Depressive Disorder Scale (SMDDS) in November 2017, the Depression Working Group 2.0 is developing 24-hour recall and momentary assessment (i.e., assessment of the severity of an MDD symptom "at this moment") measures based on the SMDDS.

Goal of the Depression Working Group 2.0

- The Depression Working Group 2.0's primary focus is to pursue qualification of the new 24hour recall measure, which is provisionally named the *Symptoms of Major Depressive* Disorder Diary (SMDDD).
- A secondary focus is to pursue qualification of a new momentary assessment measure, which is provisionally named the *Symptoms of Major Depressive Disorder Momentary* Assessment (SMDDMA).

Concept of Interest

- *SMDDD*: self-reported depression symptom severity in adults during the past 24 hours.
- SMDDMA: self-reported depression symptom severity in adults at the time the selfassessment is completed (i.e., "at this moment").

Targeted Labeling Language

- Patients treated with [*Drug X*] reported clinically significant reductions in severity of major depressive disorder compared with treatment [YY]. (*Based on group comparisons of means*)
- Compared with [YY], significantly more patients treated with [Drug X] reported clinically meaningful reductions in severity of major depressive disorder. (Based on group *comparison using responder analysis*)
- Compared with [YY], patients treated with [Drug X] reported significantly fewer days with symptoms of major depressive disorder. (*Based on group comparison of number of days to* clinically meaningful response)
- Compared with [YY], patients treated with [Drug X] reported significantly faster relief of a key subset of symptoms of major depressive disorder. (*Based on group comparison of time* to clinically meaningful response)

Milestones

Milestone	Target Date	Completed Date
Letters of Intent submission for SMDDD and SMDDMA to FDA		OCT 2018
Acceptance of <i>SMDDD</i> and <i>SMDDMA</i> by FDA into the COA Qualification Program		FEB 2019
Cognitive interview study report submission to FDA		MAR 2020
Qualification Plan submission for SMDDD to FDA		JUL 2022
Qualification Plan submission for SMDDMA to FDA		MAR 2023
Full Qualification Package submission for SMDDD to FDA	TBD	
Full Qualification Package submission for SMDDMA to FDA	TBD	

Highlights


Example Endpoint Model for Treatment of Depression

Endpoint Hierarchy	Endpoint Concept(s)	Endpoint Type
Primary	Severity of MDD symptoms	PRO (<i>SMDDD</i>)
	MDD disease severity	ClinRO
Secondary	Time to improvement for key subset of MDD symptoms	PRO (<i>SMDDMA</i>)
	Affect	ClinRO
	MDD disease severity	ClinRO

Target Population

• Persons 18 years and older with a diagnosis of MDD (depression), who are being treated in ambulatory settings

Hypothesized Conceptual Framework for the Symptoms of Major Depressive Disorder Diary (SMDDD)



Measure – Symptoms of Major Depressive Disorder Diary (SMDDD)

- **Number of Items:** 16 addressing 9 symptom domains
- **Recall Period:** Past 24 hours
- **Response Options:** 5-level verbal rating scale
- **Symptom Attribute:** Intensity or frequency as a measure of severity
- **Data Collection Mode:** Electronic data collection, specific mode to be determined

Measure – Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA)

The current version of the SMDDMA includes 11 items addressing 7 symptom domains that are suitable for momentary assessment. All item concepts from the SMDDD are represented within the SMDDMA except for 1 negative emotions/mood item, 1 cognition item, 1 sleep disturbance item, and 2 eating behavior items. Symptom attribute is intensity.



Substantive FDA Interactions

Next Steps

- Comp
- AbbV Janss Boeh Affilia Natio Resea



Working Group Activities Completed Activities

The working group modified *SMDDS* items for the shorter time frames of the new measures. In addition:

Revisions were made to 2 items to create the *SMDDD*, but all concepts were retained; Revisions were made to 4 items, and 4 items were dropped to create the SMDDMA. A cognitive interview study was subsequently conducted to obtain the additional

qualitative evidence necessary to refine the original content for shorter time frames. Nineteen qualitative interviews were completed in 4 iterative waves.

Based on evidence that emerged from the interviews, the development team agreed to revise one SMDDD item and drop one SMDDMA item.

Qualification Plans (QPs) were submitted to FDA for SMDDD (July 2022) and SMDDMA (March 2023).

Following submission of the cognitive interview study report to FDA to confirm that qualitative results together with supporting evidence from the qualified *SMDDS* were adequate to move forward with development of the QPs, the working group met with FDA's Qualification Review Team (QRT) in May 2020 to discuss their feedback.

- As a result of this discussion, one item of the *SMDDMA* was modified to align with SMDDD wording for consistency.
- The resulting 16-item *SMDDD* and 11-item *SMDDMA* were found to contain the relevant and suitable core symptom content for the specific time frame.
- FDA subsequently agreed that it was appropriate to proceed with development of QPs for both the SMDDD and SMDDMA.

• A meeting was held with FDA's QRT in July 2021, following submission by the working group of a combined SMDDD and SMDDMA quantitative pilot study protocol synopsis, including evaluation of psychometric properties. After discussion of the proposed study design, FDA agreed it was appropriate to include both measures in one combined study.

Challenges

Since the SMDDMA evaluates self-reported MDD symptom severity at the time the selfassessment is completed, a challenge within the cognitive interview phase was determining 1) which concepts participants believed were truly relevant in a momentary assessment context and 2) how the items should be worded accordingly in that context. One challenge has been to determine how best to collect quantitative data for the SMDDMA in a non-interventional setting to evaluate measurement properties (i.e., in a quantitative pilot study).

Another challenge will be to determine the appropriate way to use the MDD symptom measures together in a clinical trial setting in terms of the appropriate baseline and follow up measures (as item concepts were, in fact, removed from the SMDDMA because they were not feasible in the context of a shorter time frame so not all concepts are present).

FDA will conduct reviewability assessment followed by review of each QP. Conduct combined quantitative pilot study including *SMDDD* and *SMDDMA*

Working Group Participants

Representative	
Jonathan Stokes, MBA; Mousam Parikh, MS	
Carol Jamieson, BSc; Heather Rozjabek, PhD, MPH	
Giancarlo Maranzano, PharmD; Maarten Voorhaar, MSc	
Other Participants	
Sarah Hollingsworth Lisanby, MD	
Research Team	
Mona Martin, RN, MPA; Don Bushnell, MA	